10x Genomics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-43.5M | $-182.6M | $-255.1M | $-166.0M | $-58.2M | $-542.7M | $-31.3M | $-112.5M |
| Depreciation & Amortization | $36.2M | $35.9M | $35.5M | $25.4M | $21.1M | $14.0M | $7.1M | $3.9M |
| Depreciation | $31.2M | $33.9M | $32.9M | $22.8M | $18.5M | $12.3M | $6.7M | $3.8M |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $109.1M | $140.7M | $167.0M | $136.8M | $96.0M | $48.6M | $13.3M | $2.7M |
| Net Cash from Operating Activities | $136.1M | $6.7M | $-15.2M | $-33.6M | $-21.4M | $-217.9M | $34.6M | $-76.4M |
| Investing Activities | ||||||||
| Capital Expenditures | $5.9M | $12.4M | $48.6M | $131.7M | $101.3M | $36.7M | $42.7M | $6.3M |
| Business Acquisitions | — | $0 | $0 | $4.0M | $5.5M | $0 | $0 | — |
| Net Cash from Investing Activities | $-13.4M | $-32.6M | $133.5M | $-350.9M | $-106.7M | $-38.4M | $-42.8M | $-6.7M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $6.8M | $10.9M | $13.7M | $15.8M | $35.3M | $468.9M | $414.6M | $105.4M |
| Net Change in Cash | $129.9M | $-15.2M | $131.9M | $-368.7M | $-92.6M | $212.2M | $406.4M | $22.2M |
| Free Cash Flow | $130.1M | $-5.7M | $-63.8M | $-165.3M | $-122.7M | $-254.6M | $-8.1M | $-82.7M |